Scarica l'app Stockscreener
33.93
3.44%
-1.21
Dopo l'orario di chiusura:
34.80
0.87
+2.56%
Precedente Chiudi:
$35.14
Aprire:
$35
Volume 24 ore:
503.36K
Relative Volume:
0.47
Capitalizzazione di mercato:
$2.02B
Reddito:
-
Utile/perdita netta:
$-119.95M
Rapporto P/E:
-16.86
EPS:
-2.0123
Flusso di cassa netto:
$-95.28M
1 W Prestazione:
-3.22%
1M Prestazione:
-14.34%
6M Prestazione:
+128.95%
1 anno Prestazione:
+223.14%
Intervallo 1D:
$33.03
$35.53
Intervallo di 1 settimana:
$33.03
$36.37
Portata 52W:
$8.75
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Nome
Tyra Biosciences Inc
Settore
Industria
Telefono
(619) 728-4760
Indirizzo
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
33.93 | 2.09B | 0 | -119.95M | -95.28M | -2.0123 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | Guggenheim | Buy |
| 2026-04-06 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Iniziato | William Blair | Outperform |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-21 | Ripresa | Piper Sandler | Overweight |
| 2025-01-07 | Iniziato | UBS | Buy |
| 2024-10-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-08-15 | Iniziato | Piper Sandler | Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-30 | Iniziato | Wedbush | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-03-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2021-10-11 | Iniziato | BofA Securities | Buy |
| 2021-10-11 | Iniziato | Cowen | Outperform |
| 2021-10-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
Responsive Playbooks and the TYRA Inflection - Stock Traders Daily
Tyra Biosciences initiates partnership with KUMedCenter to advance SURF302 bladder cancer trial - Traders Union
Achondroplasia Pipeline Expands as 15+ Pharma Companies - openPR.com
TYRA SEC FilingsTyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Tyra Biosciences faces earnings test ahead of key trial data By Investing.com - Investing.com Canada
Tyra Biosciences faces earnings test ahead of key trial data - Investing.com UK
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Guggenheim initiates coverage of Tyra Biosciences (TYRA) with buy recommendation - MSN
Does Tyra Biosciences (TYRA) Board Refresh and Dabogratinib Spotlight Reframe Its Pipeline Credibility? - Sahm
Guggenheim Securities Issues Buy Rating for Tyra Biosciences - HarianBasis.co
TYRA BIOSCIENCES, INC. | SCHEDULE 13G/A: Others - Moomoo
Canaan reports 750,000 shares in Tyra Biosciences (NASDAQ: TYRA) - Stock Titan
Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib - Yahoo Finance
Understanding the Setup: (TYRA) and Scalable Risk - Stock Traders Daily
Top 10 AI-Powered Biotech Stocks to Buy Right Now - Insider Monkey
Tyra Biosciences (TYRA) Stock: Entry Strategy Overview | Q4 2025: EPS Misses EstimatesCommunity Buy Signals - Cổng thông tin điện tử tỉnh Tây Ninh
44,400 Tyra Biosciences (TYRA) stock options granted to director Dable - Stock Titan
Tyra Biosciences (TYRA) director Dable Habib J files Form 3 showing no share ownership - Stock Titan
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - 富途牛牛
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors - marketscreener.com
Tyra Biosciences adds Habib Dable to board of directors By Investing.com - Investing.com India
Yuliya Rueb Net Worth (2026) - GuruFocus
Tyra Biosciences, Inc. ($TYRA) CEO 2025 Pay Revealed - Quiver Quantitative
Cantor Fitzgerald reiterates Tyra Biosciences stock rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Tyra Biosciences stock rating - Investing.com
Tyra Biosciences appoints Habib J. Dable to board of directors By Investing.com - Investing.com Australia
Tyra Biosciences appoints Habib J. Dable to board of directors - Investing.com
Tyra Bioscience Expands Board, Appoints New Independent Director - TipRanks
Tyra Biosciences adds Habib Dable to board of directors - Investing.com
[ARS] Tyra Biosciences, Inc. SEC Filing - Stock Titan
Tyra Biosciences (TYRA) details 2026 virtual meeting, director votes and auditor - Stock Titan
Ty appoints Habib J. Dable to Board as Class II director - TradingView
Habib Dable joins Tyra Biosciences (NASDAQ: TYRA) board as Class II director - Stock Titan
Tyra Biosciences, Inc. (TYRA) Stock Analysis: Unveiling a 45.89% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Tyra Biosciences Advances Dabogratinib Trial in Niche Urothelial Cancer: What Investors Should Watch - TipRanks
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Tyra Biosciences (NASDAQ:TYRA) Stock Rating Upgraded by Guggenheim - MarketBeat
TYRA Initiates Coverage On by Guggenheim -- Price Target Announced at $54.00 - GuruFocus
This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Guggenheim Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $54 - 富途牛牛
Guggenheim Initiates Tyra Bioscience at Buy With $54 Price Target - marketscreener.com
Guggenheim Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $54 - 富途牛牛
TYRA (Nasdaq) Form 144: Director reports two 8,000-share transactions - Stock Titan
The Technical Signals Behind (TYRA) That Institutions Follow - Stock Traders Daily
Growth Stocks To Watch Today – April 10th - Defense World
JPMorgan Chase & Co. Trims Position in Tyra Biosciences, Inc. $TYRA - MarketBeat
IPO Launch: Is Tyra Biosciences Incs ROE strong enoughEntry Point & Precise Swing Trade Alerts - baoquankhu1.vn
FMR LLC holds 14.4% of Tyra Biosciences (NASDAQ: TYRA) - Stock Titan
Tyra Biosciences Inc Azioni (TYRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):